Avodart

Avodart is a prescription medicine containing dutasteride, a dual 5-alpha reductase inhibitor used to treat the symptoms of benign prostatic hyperplasia (BPH) in adult men. BPH is a non-cancerous enlargement of the prostate gland that can cause troublesome urinary symptoms, including a weak or interrupted urine stream, difficulty starting urination, the need to urinate frequently, and a persistent feeling that the bladder has not emptied fully. Avodart works by addressing the underlying hormonal cause of prostate enlargement rather than simply relaxing the muscles around the prostate.

How Avodart Works

Dutasteride blocks both type 1 and type 2 forms of the enzyme 5-alpha reductase, which is responsible for converting testosterone into dihydrotestosterone (DHT). DHT is the primary androgen driving prostate tissue growth, and by significantly reducing DHT levels in both the blood and the prostate gland, Avodart causes the prostate to shrink over time. This shrinkage relieves the mechanical obstruction of urine flow and reduces the risk of acute urinary retention, a sudden, painful inability to urinate that may require emergency catheterisation.

Who Benefits from Avodart

Avodart is suitable for adult men with a moderately to severely enlarged prostate. It is often prescribed when lifestyle changes and watchful waiting have proved insufficient, or when there is a significant risk of disease progression. Clinical studies have demonstrated that dutasteride reduces prostate volume by approximately 25% after 12 months and lowers PSA (prostate-specific antigen) levels by around 50% after six months of treatment. This PSA reduction must be accounted for when screening for prostate cancer; clinicians typically double the measured PSA value to obtain a reliable estimate.

Important Considerations

Avodart is strictly for use in men and must never be handled by women who are pregnant or who may become pregnant, as dutasteride is absorbed through the skin and can cause abnormal development of the male foetus. It is not a treatment for prostate cancer, although studies have explored its role in cancer risk reduction. Full therapeutic benefit may take six to twelve months to become apparent, and patients are advised to continue treatment as directed even if symptoms improve early. Regular prostate assessments and PSA monitoring are recommended throughout therapy.

How to Take Avodart

Take one Avodart (dutasteride) 0.5 mg capsule once daily by mouth, with or without food, at any time of day. Swallow the capsule whole, do not chew, crush, or open it, as contact with the contents can irritate the mouth and throat, and the active ingredient must not be handled by women who are pregnant.

How Long to Take Avodart

Treatment is long term. A noticeable improvement in urinary symptoms may take three to six months, and the full benefit on prostate volume and urinary flow is typically seen after 12 months or more. Do not stop treatment early without consulting your doctor, as symptoms may return.

The standard recommended dose of Avodart is 0.5 mg once daily as a single oral capsule. There is no evidence that higher doses provide additional benefit, and they are associated with an increased risk of side effects.

No dose adjustment is required in elderly patients, as clinical trials included men over 75 years without evidence of altered safety or efficacy in this age group. Avodart is not indicated for use in women or children.

For patients with mild to moderate hepatic impairment, Avodart should be used with caution because dutasteride is extensively metabolised by the liver via the CYP3A4 and CYP3A5 enzyme pathways; exposure may be increased in those with compromised liver function. It is not recommended for patients with severe hepatic impairment, as no formal pharmacokinetic studies have been conducted in this group.

Renal impairment does not require dose adjustment, as less than 0.1% of a dutasteride dose is excreted unchanged in the urine. Patients with end-stage renal disease have not been formally studied but are unlikely to require altered dosing.

Avodart is generally well tolerated, but like all medicines it can cause side effects. Most adverse effects relate to its hormonal mechanism of action and affect sexual function.

Common Side Effects

The following side effects are reported in clinical trials and affect at least 1 in 100 patients:

• Impotence (erectile dysfunction)
• Decreased libido (reduced sex drive)
• Ejaculation disorders, including reduced semen volume
• Breast tenderness or enlargement (gynaecomastia)
• Dizziness, particularly in the first few months of treatment
• Rash or urticaria (hives) in some patients

These sexual side effects are most commonly reported during the first year of treatment and may diminish with continued use.

Serious Side Effects

The following serious reactions require prompt medical attention:

• Severe allergic reaction (anaphylaxis): sudden difficulty breathing, swelling of the face, lips, tongue, or throat, or severe skin rash, seek emergency help immediately
• Angioedema (deep tissue swelling of the face or throat)
• Signs of prostate or other pelvic cancers: Avodart reduces PSA, which may mask early prostate cancer; regular monitoring is essential
• Severe liver reactions: jaundice, persistent nausea, right upper abdominal pain, although rare, these have been reported post-marketing
• Male breast cancer: a small number of cases have been reported in men taking dutasteride, and any breast lump or nipple discharge should be evaluated promptly

Hormonal and Reproductive Warnings

Avodart must not be used by women or children. Dutasteride is absorbed through the skin and poses a risk of feminising a male foetus during the first trimester of pregnancy. Women who are pregnant or may become pregnant must not handle Avodart capsules. If skin contact with a leaking capsule occurs, the area should be washed thoroughly with soap and water immediately.

Men taking Avodart should use a condom during sexual intercourse with a woman who is pregnant or may become pregnant, as dutasteride is present in semen. Men should not donate blood while taking Avodart or for six months after stopping treatment, because donated blood might be transfused to a pregnant woman.

PSA Monitoring and Cancer Screening

Dutasteride reduces PSA concentrations by approximately 50% after six months of treatment. This effect persists throughout therapy. Clinicians must account for this when interpreting PSA results: the measured value should be doubled to compare with the normal reference range and to detect a meaningful rise that might indicate prostate cancer. Any sustained increase in PSA while on Avodart warrants investigation.

Drug Interactions and Other Precautions

Dutasteride is metabolised by CYP3A4 enzymes; potent inhibitors of this pathway (such as ritonavir, ketoconazole, and verapamil) may increase dutasteride blood levels. Caution is advised, and prescribers should review the full medicine list before starting Avodart. There is no clinically significant interaction with alcohol, but patients with liver disease require monitoring. Men wishing to father children should be aware that Avodart may affect sperm quality and male fertility during treatment.

Avodart must not be used in the following circumstances:

• Women (all ages)
• Children and adolescents under 18 years of age
• Patients with known hypersensitivity to dutasteride, other 5-alpha reductase inhibitors, or any of the capsule excipients
• Patients with severe hepatic impairment
• Men who are considering fathering a child in the near future (due to potential effects on sperm and foetal development)
• Blood donors (during treatment and for six months after stopping)
• Patients whose partner is pregnant or may become pregnant and who cannot use barrier contraception